Brief: Tscan Therapeutics Receives FDA’S Regenerative Medicine Advanced Therapy (Rmat) Designation For Its Two Lead Tcr-T Therapy Candidates For The Treatment Of Heme Malignancies
29/05/2024 12:06
May 29 (Reuters) - TScan Therapeutics Inc TCRX.O :
* TSCAN THERAPEUTICS RECEIVES FDA’S REGENERATIVE MEDICINE
ADVANCED
THERAPY (RMAT) DESIGNATION FOR ITS TWO LEAD TCR-T THERAPY
CANDIDATES FOR THE TREATMENT OF HEME MALIGNANCIES
Source text for Eikon: ID:nGNX1Wr0Sp
Further company coverage: TCRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tscan Therapeutics
See all newsU.S. RESEARCH ROUNDUP-Broadcom, Deere & Co, Snowflake
U.S. STOCKS ON THE MOVE-FuelCell, Gold miners, NetApp
U.S. STOCKS ON THE MOVE-AEVEX, Sirius XM, PG&E
U.S. STOCKS ON THE MOVE-TScan Therapeutics, EOS Energy, Brown-Forman Corp
Brief: TScan Therapeutics - Amgen To Terminate Research Collaboration And License Agreement With TScan Therapeutics - SEC Filing